TILT Holdings Resultados de beneficios anteriores
Pasado controles de criterios 0/6
TILT Holdings has been growing earnings at an average annual rate of 42.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 5.6% per year.
Información clave
42.2%
Tasa de crecimiento de los beneficios
49.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | 5.6% |
| Rentabilidad financiera | -450.5% |
| Margen neto | -52.1% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero TILT Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 146 | -76 | 34 | 0 |
| 31 Mar 24 | 161 | -67 | 34 | 0 |
| 31 Dec 23 | 166 | -62 | 38 | 0 |
| 30 Sep 23 | 173 | -114 | 42 | 0 |
| 30 Jun 23 | 169 | -121 | 44 | 0 |
| 31 Mar 23 | 174 | -101 | 49 | 0 |
| 31 Dec 22 | 174 | -107 | 49 | 0 |
| 30 Sep 22 | 184 | -54 | 47 | 0 |
| 30 Jun 22 | 197 | -38 | 47 | 0 |
| 31 Mar 22 | 198 | -30 | 44 | 0 |
| 31 Dec 21 | 203 | -35 | 42 | 0 |
| 30 Sep 21 | 191 | -60 | 43 | 0 |
| 30 Jun 21 | 177 | -63 | 40 | 0 |
| 31 Mar 21 | 165 | -73 | 40 | 0 |
| 31 Dec 20 | 158 | -52 | 40 | 0 |
| 30 Sep 20 | 144 | -28 | 33 | 0 |
| 30 Jun 20 | 151 | 0 | 0 | 0 |
| 31 Mar 20 | 153 | -40 | 55 | 0 |
| 31 Dec 19 | 147 | -122 | 122 | 0 |
| 30 Sep 19 | 122 | -638 | 153 | 0 |
| 30 Jun 19 | 77 | -671 | 185 | 0 |
| 31 Mar 19 | 38 | -626 | 126 | 0 |
| 31 Dec 18 | 4 | -550 | 52 | 0 |
Ingresos de calidad: TLLT.F is currently unprofitable.
Margen de beneficios creciente: TLLT.F is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: TLLT.F is unprofitable, but has reduced losses over the past 5 years at a rate of 42.2% per year.
Acelerando crecimiento: Unable to compare TLLT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: TLLT.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rentabilidad financiera
Alta ROE: TLLT.F has a negative Return on Equity (-450.51%), as it is currently unprofitable.